A B S T R A C T Tissue sensitive to insulin and insulin binding to monocytes were evaluated in 15 nonobese maturity-onset diabetics and in 16 healthy controls. Insulin sensitivity was determined by the insulin clamp technique in which the plasma insulin is acutely raised and maintained 100 .U/ml above the fasting level and plasma glucose is held constant at fasting levels by a variable glucose infusion. The amount of glucose infused is a measure of overall tissue sensitivity to insulin.
A B S T R A C T Tissue sensitive to insulin and insulin binding to monocytes were evaluated in 15 nonobese maturity-onset diabetics and in 16 healthy controls. Insulin sensitivity was determined by the insulin clamp technique in which the plasma insulin is acutely raised and maintained 100 .U/ml above the fasting level and plasma glucose is held constant at fasting levels by a variable glucose infusion. The amount of glucose infused is a measure of overall tissue sensitivity to insulin.
In the diabetic group, the fasting plasma glucose concentration (168±4 mg/dl) was 85% greater than controls (P < 0.01) whereas the plasma insulin level (15±1 ,U/ml) was similar to controls. During the insulin clamp study, comparable plasma insulin levels were achieved in the diabetics (118±5) and the controls (114±5 ,uU/ml). However, the glucose infusion rate in the diabetics (4.7±0.4 mg/kg min) was 30% below controls (P < 0.01). Among the diabetics, the glucose infusion rate correlated directly with the fasting plasma glucose level (r = 0.57, P < 0.05). In five diabetic subjects, glucose metabolism was similar to controls, and these diabetics had the highest fasting glucose levels. When they were restudied after prior normalization (with insulin) of the fasting plasma glucose (100±1 mgldl), the glucose infusion rate during the insulin clamp was 30% lower than observed in association with hyperglycemia (P < 0.01). Studies that employed tritiated glucose to measure endogenous glucose production indicated comparable 90-95% inhibition of hepatic glucose production during hyperinsulinemia in the diabetic and control subjects.
1251-insulin binding to monocytes in the diabetics (5.5±0.6%) was 30% below that in controls (P < 0.01). Received for publication 20 July 1978 and in revised form 24 November 1978. Insulin binding to monocytes and insulin action as determined with the insulin clamp were highly correlated in both control (r = 0.67, P < 0.01), and diabetic subjects (r = 0.88, P < 0.001).
We conclude that (a) tissue sensitivity to physiologic hyperinsulinemia is reduced in most maturity-onset diabetics; (b) this decrease in sensitivity is located, at least in part, in extrahepatic tissues; (c) the resistance to insulin may be mediated by a reduction in insulin binding; and (d) in maturity-onset diabetics with normal tissue sensitivity to insulin, hyperglycemia may be a contributing factor to the normal rates of insulinmediated glucose uptake.
INTRODUCTION
Insulin deficiency is generally recognized as the primary pathogenetic factor in the development ofjuvenile-onset diabetes (1) . In contrast, in maturity-onset diabetes there is evidence of insulin deficiency as well as insulin resistance. Perley and Kipnis (2) and Bagdade et al. (3) observed a decreased insulin response to glucose in nonobese as well as obese subjects with maturity-onset diabetes when compared with weight-matched controls. On the other hand, Reaven et al. (4, 5) and other workers (6-8) have reported normal or increased insulin levels in maturity-onset diabetes, thus suggesting a role for insulin resistance in the pathogenesis of this disorder.
With respect to insulin resistance, Alford et al. (9) noted a blunted decline in plasma glucose concentration during an intravenous insulin tolerance test in maturity-onset diabetes with fasting hyperglycemia. However, the overall plasma glucose response to intravenous insulin depends not only upon tissue sensitivity to insulin but also on the counterregulatory hormone response to the insulin-induced hypoglycemia (10) . More recently, Reaven et al. (11) (12) (13) (14) have employed an infusion technique which involves the administration of insulin, glucose, epinephrine, and propranolol. They documented higher steady-state plasma glucose levels in maturity-onset diabetics than in healthy controls and interpreted their findings as indicative of "impedance" to insulin-mediated glucose uptake. However, these results are open to question as epinephrine may of itself decrease tissue sensitivity to insulin (15) (16) (17) . Furthermore, whether the simultaneous infusion ofpropranolol fully eliminates the insulinantagonistic effects of epinephrine or exerts its own effects on peripheral glucose uptake is unknown. Harano et al. (18) have attempted to circumvent this problem by -substituting somatostatin for epinephrine and propranolol in the combined glucose-insulin infusion technique. With this modification they also found higher steady-state plasma glucose levels in diabetics (18) . However, recent studies have suggested that somatostatin per se may alter the hepatic response to glucoregulatory hormones (19 Insulin clamp study. Sensitivity to the in vivo action of insulin was determined by the insulin clamp technique as previously described (20, 22) . Briefly, after a control period of 180-210 min, a priming plus continuous infusion (42.6 mU/M2 surface area per minute) of crystalline porcine insulin (Eli Lilly and Co., Indianapolis, Ind.) was administered for a total of 120 min to obtain constant physiologic hyperinsulinemia (20, 22) . The plasma glucose level was maintained at basal preinfusion levels by determination of the plasma glucose concentration every 5 min and the periodic adjustment of a variable infusion of a 20% glucose solution. Under these steady-state conditions of constant euglycemia, all of the glucose infused is taken up by cells and thus serves as a measure of the amount of glucose metabolized (M)l by the entire body in response to the infused insulin.
Endogenous glucose production. The effect ofthe insulinglucose infusion (insulin clamp) on endogenous glucose production was determined by the infusion of tritiated glucose as previously described (22, 23) . For 3 h before initiating the insulin infusion, each subject's glucose pool was labeled by a priming (25 sCi) plus continuous (0.25 ,uCi/min) infusion of [3-3H] glucose (New England Nuclear, Boston, Mass.). Basal hepatic glucose production was calculated from the specific activity plateau achieved during the 3rd h of [3-3H] glucose infusion. After 3 h of continuous [3-3H] glucose infusion the insulin clamp study was begun, and the continuous infusion of [3-3H] glucose was continued at the same rate.
Repeat insulin clamp studies in diabetics at normal plasma glucose levels. Because hyperglycemia has been suggested to potentiate the effect of insulin on target tissues (24) (25) (26) , and inasmuch as basal glucose levels were higher in the diabetics than in controls, we performed repeat insulin clamp studies in the five diabetic subjects who demonstrated the highest rates of insulin-mediated M as determined by the initial clamp study. In these repeat studies, the plasma glucose level was normalized with the insulin infusion before initiating the variable glucose infusion. After the insertion of catheters, four base-line plasma samples were drawn at 10-min intervals, and a prime-continuous insulin infusion was administered as described above for the initial study. However, no glucose was administered until the plasma glucose concentration had diminished to 100-110 mg/dl. At this time, a variable glucose infusion was begun and adjusted so as to maintain the plasma glucose concentration at 100 mg/dl for a period of 120 min. All subjects reached a plasma glucose concentration of 100 mg/dl within 60-80 min after starting the insulin infusion. Studies with [3-3H]glucose were not performed during these repeat infusions.
125I-Insulin binding study. Insulin binding to monocytes was measured in all subjects by modification ofthe technique of Gavin et al. (27) as described previously (22) . Nonspecific binding of '25I-insulin to monocytes, as defined by the amount of 125I-insulin bound to the cell pellet in the presence of 105 ng/ml of insulin, was 0.3-0.5% of the total radioactivity for both normal and diabetic patients. The nonspecific binding was subtracted from total binding to give the specific binding. 1251-insulin specifically bound is expressed per 1 x 107 monocytes. In two of the diabetic subjects, insulin binding was determined in the basal state and at the completion of the repeat insulin clamp studies performed at normal plasma glucose levels. In two control subjects, insulin binding was also determined in the basal state and again at the end of the insulin clamp study. The calculations employed in the determination of glucose production in the basal state and during the insulin clamp, as well as the calculations employed in analyzing the insulin binding data, have been described previously (22) .
All data are presented as the mean+SEM. All statistical comparisons between the diabetic and control groups were calculated by unpaired t test analysis (28) . In the five diabetic subjects studied at hyperglycemic and normal glucose levels, the amounts ofM during the 60-to 120-min time period were compared by paired t test analysis (28) . Coefficients of correlation were determined by standard procedures (28) .
Analytical procedures. Plasma glucose was determined with the glucose oxidase method (Glucostat, Beckman Instruments, Inc., Fullerton, Calif.). Methods for the determination of plasma immunoreactive glucagon (with Unger 30K antibody) and insulin (29) , as well as the specific activity of plasma glucose (22, 23) , have previously been described.
RESULTS
Insulin clamp studies at basal plasma glucose concentrations (Table I) Control subjects. During the insulin infusion, plasma insulin rose to a steady-state concentration which was 100-105 ,uU/ml above the basal level. The stability of the plasma insulin concentration is indicated by the coefficient of variation which was 8±1%. The calculated MCR of insulin was 434±25 mi/M2-min.
The plasma glucose concentration was maintained at basal fasting levels throughout the period of hyperinsulinemia with a coefficient of variation of3.9±0.2%. The amount of glucose infused to maintain euglycemia was 6.28±0.30 mg/kg-min. Plasma glucagon fell 30% during the insulin infusion.
Diabetic subjects. The fasting plasma insulin concentration was similar to controls. The prime-continuous insulin infusion resulted in steady-state plasma insulin levels which were virtually identical to controls. The coefficient of variation for the plasma insulin concentration was 7+1%. The MCR of insulin was calculated as 420+21 mg/M2 min, which was similar to the value observed in controls.
The fasting plasma glucose concentration in the diabetics was 85% greater than controls (P < 0.01). During the period of hyperinsulinemia, the plasma glucose was maintained at fasting hyperglycemic levels with a coefficient of variation of 3.4+±0.3%. The amount of glucose infused to maintain the glucose concentration at the basal level was 25% below that observed in the controls (P < 0.01). Plasma glucagon fell by 30% during the insulin infusion and was comparable to the values in control subjects.
In Fig. 1 , the individual values for the amount of M in the control and diabetic subjects are shown. Although the mean value was significantly lower in the diabetics (P < 0.01), in five ofthe diabetic subjects the amount of M was comparable to that observed in the controls. For the diabetic group as a whole, a direct linear correlation was observed between the amount ofM and the fasting plasma glucose concentration (r = 0.57, P < 0.05).
Repeat insulin clamp in diabetics at normal plasma glucose concentrations (Table II) Because hyperglycemia has been implicated as a positive modulator of insulin-mediated M (24-26), and in view ofthe positive correlation between the amount ofM and fasting hyperglycemia in the diabetics during the insulin clamp study, the five diabetic subjects with the highest amounts of M, when studied at elevated plasma glucose levels ( Fig. 1) , were restudied at normal plasma glucose concentration (Table II) .
During the initial 60 min ofthe repeat insulin clamp, the plasma glucose concentration was lowered from fasting levels of 204+29 to 100-110 mg/dl by the infusion of insulin alone. Between 60 and 120 min the plasma glucose level was maintained at 100±1 mg/dl with a coefficient of variation of 3.2±0.4% by the combined infusion of glucose and insulin. The amount of glucose infused to maintain euglycemia was 30% below that infused in the same subjects during the initial study at hyperglycemic levels (P < 0.01). The value for M in the repeat study was also 30% below that observed in control subjects (Table I ) studied at comparable plasma glucose concentrations (P < 0.02). The plasma insulin concentration during the insulin infusion was comparable to that observed in the initial study in the diabetics and the study in the controls (Table I) . Its constancy is indicated by the coefficient of variation of 6.6+0.5% during the 20-to 120-min time interval.
Endogenous glucose production Table III shows the values for glucose production in the control and diabetic subjects. In the basal state, mean glucose production in the diabetics was slightly (15%) but not significantly greater than in controls (P > 0.10). During the insulin clamp, there was a 90-95% suppression of endogenous glucose production, which was similar in the two groups of subjects.
125-Insulin binding to monocytes
In the control subjects the total specific binding of 1251-insulin was 7.8+0.4%/i x 107 monocytes. In the diabetic patients this value (5.5+0.6%) was 30% lower than in controls (P < 0.01). As is evident from the competition curves of 1251-insulin binding (Fig. 2) , the amount of insulin bound was significantly less in the diabetic subjects than in controls at all insulin concentrations up to 100 ng/ml (P < 0.05). Scatchard analysis (Fig. 3) of the insulin binding data revealed curvilinear plots in both the control and diabetic subjects. The total insulin binding capacity, as represented by the intercept at the abscissa (Fig. 3) , was significantly lower in the diabetic group (1.0+0. 12 ng/ml per 1 x 107 monocytes) than in the control subjects (1.45±0.08 ng/ml, P < 0.01). The calculated number of insulin binding sites in the diabetic subjects (10,000+1,200 sites per monocyte) was 30% below that of controls (14,500+800, P < 0.01). When insulin binding affinity was analyzed by the average-affinity profile plot method (30), we found that the average-affinity plots in the diabetic subjects were virtually identical to that ofcontrol subjects. The highest or "empty site" binding affinity (Ke) in the diabetics (0.37+0.04 nM-t) was similar to that of controls (0.36+0.03 nM-5, P > 0.5). Similarly, the lowest binding affinity (Kf) was also identical in the control (0.05+0.007 nM-') and the diabetic subjects (0.06+0.007 nM-t, P > 0.5).
In two of the diabetic subjects, insulin binding to monocytes was similar in the basal state (5.9%) and after completion of insulin clamp study (5.9%). Likewise, no change in insulin binding was observed in the two control subjects in whom insulin binding was determined before (8.3%) and at the end (7.9%) of the insulin clamp.
Relationship between insulin binding, plasma insulin concentration, and insulin action An inverse relationship was demonstrable between the fasting plasma insulin concentration and insulin binding to circulating monocytes in both the control subjects (r = -0.787, P < 0.001) and the diabetics (r represented by intercepts at the abscissa.
= -0.796; P < 0.001) (Fig. 4) . In Fig. 5 , the relationship between total specific binding of insulin and insulinmediated M as reflected by the amount of M during the insulin clamp studies is shown. When the normal control subjects are examined alone, a highly significant, direct, linear correlation between insulin binding and insulin-mediated M was observed (r = 0.674; P <0.01). A similar direct correlation was observed among the diabetic subjects (r = 0.880, P < 0.001) and also when both groups were combined (r = 0.925; P < 0.001). Because the decrease in total specific binding of insulin to monocytes in diabetic patients was mainly (26) . Thus, the glucose infusion insulin (per 1 x 107 monocytes/ml) at tracer (0.2 ng/ml) concentration of insulin and the in vivo insulin sensitivity (as rate necessary to maintain basal plasma glucose levels indicated by the amount of M during the insulin clamp), in is determined by the net uptake of glucose in peripheral control and MOD. The correlation coefficient (r) of the and extrahepatic tissues (muscle and adipose tissue), combined control and diabetic groups is shown. and the extent of inhibition of hepatic glucose production. The studies with [3-3H] glucose permitted a result of a decrease in the number of insulin binding us to examine endogenous glucose production. As sites, we also examined the correlation between the indicated in Table III , the insulin clamp procedure number of insulin binding sites per monocyte and in-produced comparable inhibition of endogenous glusulin-mediated M. We found a highly significant, direct cose production in the diabetic and control subjects. correlation between these parameters in the controls These data thus indicate that the site of insulin (r = 0.784; P < 0.001), the diabetic subjects (r = 0.934, resistance in MOD resides at least in part in peripheral, P < 0.001), and when both groups were combined extrahepatic tissues. It should, however, be noted that (r = 0.859, P < 0.001).
whereas these studies have examined hepatic glucose production, they have not evaluated the action of in-DISCUSSION sulin on glucose uptake by the liver. Thus, conclusions regarding hepatic sensitivity to insulin-mediIn this study, in vivo sensitivity to physiologic ated glucose uptake cannot be drawn from these data. hyperinsulinemia was examined in nonobese MOD by Of note in this study is the observation that whereas means of the insulin clamp technique. As compared the diabetics as a group demonstrated a significant rewith previous studies of insulin sensitivity in diabetes duction in insulin-mediated M, five of the diabetic subinvolving either the bolus intravenous injection of in-jects, when studied at basal hyperglycemic levels, sulin (9) or the infusion of insulin and glucose (in a demonstrated rates of insulin-mediated M which were predetermined dose) combined with epinephrine and comparable to controls (Fig. 1) . The basis for this hetpropranolol (11) (12) (13) (14) , the insulin clamp procedure offers erogeneity of insulin sensitivity in the diabetic group several advantages. First, the complex neuroendocrine cannot be established with certainty from these present response to insulin-induced hypoglycemia is avoided data. However, it is noteworthy that the five MOD by maintaining the plasma glucose at basal concen-with the highest rates of insulin-mediated glucose trations. Second, the infusion procedure does not in-metabolism had the highest fasting plasma glucose convolve the administration ofepinephrine or propranolol, centrations. Indeed, among the diabetics, a direct corwhich may of themselves alter sensitivity to insulin. relation was observed between fasting plasma glucose Third, because the plasma glucose concentration is levels and insulin-mediated M. Furthermore, when the maintained constant, the amount of glucose infused plasma glucose level was normalized in the diabetic (minus any glucose lost in the urine) provides an index subjects by the (Fig.  5) . This relationship was similar whether the normal and diabetic subjects were considered separately or collectively. To the extent that the monocyte is reflective of changes in binding in target tissues of insulin action, such as the liver and fat cell (33) , these data suggest that insulin insensitivity in maturity-onset diabetes is mediated at least in part by changes in receptor binding. This conclusion is in agreement with previous studies demonstrating a relation between changes in insulin sensitivity and insulin binding in MOD treated with sulfonylurea agents (34) . In addition, as in the case of normal (22) , obese (22) , and growth-hormone deficient subjects (35) studied in the postabsorptive state, these findings indicate that in MOD, insulin binding to monocytes constitutes an index of total body sensitivity to physiologic hyperinsulinemia.
Although mean basal insulin levels were comparable in the diabetics and controls, an inverse relation between fasting plasma insulin concentration and insulin binding to monocytes was observed in both groups (Fig. 4) . These observations are in keeping with previous data indicating that insulin regulates its own receptor (30) . It should, however, be noted that the insulin response to glucose or other stimuli was not investigated in this study. Thus, the extent to which decreased secretion of insulin may have contributed to the development of hyperglycemia in the diabetic group cannot be determined from these4ata. Nevertheless, these data suggest that insulin insensitivity in maturity-onset diabetes is mediated at least in part by changes in receptor binding.
Finally, no differences were observed between the normal and diabetic group with respect to the MCR of insulin. Thus, in circumstances of hyperinsulinemia or hypoinsulinemia in MOD, altered hormonal secretion rather than changes in hormone degradation appears to be the responsible mechanism. These data are in keeping with previous observations using isotopic techniques (36) .
